Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) was down 2.3% during mid-day trading on Wednesday . The stock traded as low as $115.00 and last traded at $115.00. Approximately 505 shares were traded during trading, a decline of 75% from the average daily volume of 1,987 shares. The stock had previously closed at $117.77.
Zealand Pharma A/S Trading Down 2.3 %
The firm has a market cap of $5.92 billion, a price-to-earnings ratio of -63.19 and a beta of 0.95. The company has a debt-to-equity ratio of 0.03, a quick ratio of 35.57 and a current ratio of 35.57. The company's 50-day moving average is $128.10 and its 200-day moving average is $111.76.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.06). The firm had revenue of $4.93 million for the quarter, compared to the consensus estimate of $0.50 million. Zealand Pharma A/S had a negative return on equity of 18.17% and a negative net margin of 191.92%. On average, research analysts predict that Zealand Pharma A/S will post -2.29 earnings per share for the current year.
Zealand Pharma A/S Company Profile
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
